Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT07294313
Starting soon Observational

Harnessing Artificial Intelligence for Diagnosing Androgenetic Alopecia: A Training and Validation Study

NCT07294313 · tracked via the Priya Life Science Egypt tracker
Sponsor
Cairo University
Phase
Observational
Started
2026-04-25
Last updated
2026-03-20

Condition(s) studied

Androgenetic Alopecia

Study summary

The aim of this study is to develop and validate deep learning models in diagnosis of male and female pattern hair loss, and assessment of its severity based on clinical and trichoscopic image by handheld dermoscopy and administrative data (age and sex).

Eligibility

Sex
ALL
Min age
12 Years
Max age
50 Years
Healthy volunteers
Accepted
for the patient group: Inclusion criteria: * Patients with male or female pattern hair loss diagnosed clinically or suspected clinically and confirmed trichoscopically * Age of disease onset 12-50 years old * Both genders * Any grade of androgenetic alopecia * Any duration of androgenetic alopecia * Any skin type Exclusion criteria by clinical and trichoscopic examination: * Patients with patchy hair loss or Telogen effluvium only. * Patients with cicatricial alopecia or diffuse alopecia areata * Patients with inflammatory scalp disorders (psoriasis, seborrheic dermatitis, lichen planopilaris and frontal fibrosing alopecia in a pattern distribution) * Lack of patient cooperation. for the control group: apparently healthy participants not suffering from the following: AGA, patchy hair loss, cicatricial alopecia, diffuse alopecia areata, inflammatory scalp disorders (psoriasis, seborrheic dermatitis, lichen planopilaris and frontal fibrosing alopecia in a pattern distribution).

Primary outcome measure(s)

  • assessment of diagnostic capability of AI in AGA — 1 year
    Assess accuracy, sensitivity, specificity and positive predictive value of the trained AI models in differentiating AGA affected from non-AGA affected subjects using their macroscopic and trichoscopic images.

Trial sites (1)

FacilityCityRegionStatus
Faculty of Medicine Cairo University Cairo Cairo Governorate

More Cairo University trials in Egypt

Comparison Between Egyptian MTA, Biodentine Versus Calcium Hydroxide as Indirect Pulp Capping Materials In Permanent Teeth Recruiting
Effect of Thoracic Mobilization in People With Central Obesity Active, not recruiting
Transanal vs Transvaginal Rectal Resection for Anterior Rectocele Recruiting
The Association Between Abdominal Obesity, Gluteal Muscles Strength and Endurance in Young and Middle-aged Adults. Active, not recruiting
Relationship Between Facial Palsy and Psychological Distress Starting soon

Other trials for the same condition

The Effect of Nanofat Injection on Androgenetic Alopecia Starting soon
JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil Recruiting
Evaluation of Exosomes Injection in Treatment of Male Androgenetic Alopecia: Clinical and Immunohistochemical Study Starting soon
Efficacy of Botulinum Toxin A Versus Nanofat in the Treatment of Androgenetic Alopecia: A Comparative Clinical Trial Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07294313 on ClinicalTrials.gov ↗ ← All trials in Egypt